Accuray has proclaimed that it is planning to display the CyberKnife Robotic Radiosurgery System in the company booth #3243, during the American Urological Association (AUA) meeting, which would be held from May 14 to 17 in Washington, D.C.
This system has been utilized for the treatment of more than 6500 prostate cancer patients worldwide. It would also support a theater presentation on the usage of the CyberKnife System for treating prostate cancer highlighting the CyberKnife Prostate SBRT outcomes.
According to Omar Dawood, Accuray’s Vice President of medical affairs, the latest data published for a five year period on CyberKnife SBRT for prostate cancer would confirm the enduring effectiveness of prostate SBRT adding to the ever increasing clinical evidence in favor of the CyberKnife System for prostate cancer. Dawood states that the singular capacity of their robotic technology which could both identify and rectify prostate movement has helped them to continue to lead in the prostate SBRT field. He revealed that the during the first quarter of 2011, the company had pulled off a 20% increase in the prostate cancer treatments all over the world and that they were eager to continue the growth of this option.
Accuracy would hold a presentation on May 17 at the AUA Industry Clinical Update Theatre, wherein Lee Ponsky who is the MD FACS Director of the Center for Urologic Oncology and Minimally Invasive Therapies at University Hospitals Case Medical Center located in Cleveland, along with Debra Freeman, who is the Senior Manager of Clinical Development at Accuray would give an overview of the Cyberknife Prostate SBRT Outcomes and Experiences. After which, a discussion on the responsibilities of the surgeons in a multi-disciplinary team for treatment of prostate cancer patients with SBRT would take place.
Source: http://www.accuray.com